MORF Morphic Holding Inc.
NewsSee all news
-
Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
-
Morphic to Present at the Jefferies 2019 London Healthcare Conference
WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
-
Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results
MORF-720, αvβ6-targeted oral integrin inhibitor IND now anticipated in the second half of 2020α4β7-targeted oral integrin inhibitor candidate for IBD on track for IND by mid-2020Morphic ends third quarter of 2019 with
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Latest News
-
Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
-
Morphic to Present at the Jefferies 2019 London Healthcare Conference
WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
-
Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results
MORF-720, αvβ6-targeted oral integrin inhibitor IND now anticipated in the second half of 2020α4β7-targeted oral integrin inhibitor candidate for IBD on track for IND by mid-2020Morphic ends third quarter of 2019 with